In contrast, a large retrospective analysis (n = 656) of a Clinico-Genomic Database evaluating outcomes in a real-world setting demonstrated that after the first line of immunotherapy, the median OS of NRAS mutant melanomas was 44.9 months compared to 38.6 months in BRAF mutants, 27.1 months in NF1 mutants, and 19.8 months in triple wild-type melanomas [89]. The gene discussed is NRAS; the disease is melanoma.